CINECA IRIS Institutional Research Information System

BERTANI, LORENZO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.904
AS - Asia 2.314
EU - Europa 1.580
SA - Sud America 536
AF - Africa 137
OC - Oceania 21
Continente sconosciuto - Info sul continente non disponibili 4
Totale 8.496
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.800
SG - Singapore 802
CN - Cina 519
IT - Italia 457
BR - Brasile 442
HK - Hong Kong 362
VN - Vietnam 279
SE - Svezia 216
DE - Germania 178
FR - Francia 133
GB - Regno Unito 131
BG - Bulgaria 116
AT - Austria 82
IN - India 80
FI - Finlandia 75
CA - Canada 59
RU - Federazione Russa 59
JP - Giappone 46
TR - Turchia 44
CI - Costa d'Avorio 43
NL - Olanda 39
AR - Argentina 29
MX - Messico 27
BD - Bangladesh 25
PL - Polonia 24
IQ - Iraq 22
NG - Nigeria 22
SN - Senegal 22
ID - Indonesia 21
AU - Australia 20
EC - Ecuador 19
UZ - Uzbekistan 15
ZA - Sudafrica 13
SA - Arabia Saudita 12
PK - Pakistan 11
VE - Venezuela 11
IR - Iran 10
UA - Ucraina 10
ES - Italia 9
BE - Belgio 8
CO - Colombia 8
JO - Giordania 8
KR - Corea 8
KE - Kenya 7
MY - Malesia 7
PE - Perù 7
PY - Paraguay 7
UY - Uruguay 7
CH - Svizzera 6
EG - Egitto 6
LT - Lituania 6
MA - Marocco 6
PH - Filippine 6
CL - Cile 5
NP - Nepal 5
TW - Taiwan 5
JM - Giamaica 4
KZ - Kazakistan 4
SK - Slovacchia (Repubblica Slovacca) 4
TN - Tunisia 4
AL - Albania 3
AZ - Azerbaigian 3
CR - Costa Rica 3
EU - Europa 3
IL - Israele 3
QA - Qatar 3
SI - Slovenia 3
AO - Angola 2
BA - Bosnia-Erzegovina 2
CZ - Repubblica Ceca 2
DK - Danimarca 2
DZ - Algeria 2
ET - Etiopia 2
GH - Ghana 2
KG - Kirghizistan 2
KH - Cambogia 2
LB - Libano 2
LV - Lettonia 2
MD - Moldavia 2
NI - Nicaragua 2
PA - Panama 2
PT - Portogallo 2
TT - Trinidad e Tobago 2
AE - Emirati Arabi Uniti 1
AF - Afghanistan, Repubblica islamica di 1
BB - Barbados 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BY - Bielorussia 1
CG - Congo 1
DO - Repubblica Dominicana 1
GR - Grecia 1
GT - Guatemala 1
HN - Honduras 1
HU - Ungheria 1
IE - Irlanda 1
KW - Kuwait 1
LI - Liechtenstein 1
LK - Sri Lanka 1
LU - Lussemburgo 1
Totale 8.482
Salva come PNG Salva come JPEG
Città #
Ashburn 484
Singapore 389
Dallas 365
Hong Kong 352
Santa Clara 311
San Jose 308
Fairfield 231
Chandler 206
Woodbridge 152
Shanghai 151
Ann Arbor 126
Sofia 116
Houston 114
New York 100
Seattle 90
Wilmington 85
Cambridge 84
Los Angeles 83
Ho Chi Minh City 77
Beijing 75
Boardman 75
Serra 74
Florence 71
London 69
Vienna 63
Princeton 62
Lawrence 53
Lauterbourg 52
Hanoi 50
Milan 47
Munich 47
Abidjan 43
Frankfurt am Main 43
Medford 42
Tokyo 40
Helsinki 36
Council Bluffs 34
São Paulo 31
Redondo Beach 30
Pisa 28
Istanbul 27
Orem 25
Ottawa 24
Dakar 22
Lagos 22
Buffalo 20
Bremen 19
Turku 18
Haiphong 16
Falkenstein 15
Lucca 15
Nuremberg 15
Redmond 15
Tashkent 15
Amsterdam 14
Chennai 14
Dearborn 14
San Diego 14
Denver 13
Des Moines 13
Dong Ket 13
Toronto 13
Baghdad 12
Warsaw 12
Da Nang 11
Groningen 10
Mumbai 10
Phoenix 10
Rome 10
Belo Horizonte 9
Guayaquil 9
Lappeenranta 9
Montreal 9
Nanjing 9
Ogden 9
Redwood City 9
Boulder 8
Brussels 8
Dhaka 8
Izmir 8
Montignoso 8
Norwalk 8
Rio de Janeiro 8
Stockholm 8
Amman 7
Changsha 7
Chicago 7
Düsseldorf 7
Hải Dương 7
Johannesburg 7
Kent 7
Mexico City 7
Montevideo 7
Nairobi 7
Naples 7
Paris 7
Quanzhou 7
Brasília 6
Brooklyn 6
Charlotte 6
Totale 5.576
Salva come PNG Salva come JPEG
Nome #
Lactobacillus Casei DG® in Patients with Irritable Bowel Syndrome: Not Only a Change of the Gut Microbiota. A Pilot Study 235
Assessment of serum cytokines predicts clinical and endoscopic outcomes to vedolizumab in ulcerative colitis patients 225
Esophageal chemical clearance and baseline impedance values in patients with chronic autoimmune atrophic gastritis and gastro-esophageal reflux disease 202
Trajectories of oral budesonide use in Crohn's disease cohort of Tuscan patients (Italy) 195
Pros and Cons of the SeHCAT Test in Bile Acid Diarrhea: A More Appropriate Use of an Old Nuclear Medicine Technique 194
Serum triiodothyronine-to-thyroxine (T3/T4) ratio predicts therapeutic outcome to biological therapies in elderly IBD patients 193
Irritable bowel syndrome and chronic constipation: Fact and fiction 190
Proton pump inhibitor responders who are not confirmed as GERD patients with impedance and pH monitoring: who are they? 188
Serum triiodothyronine-to-thyroxine (T3/T4) ratio predicts therapeutic outcome to biological therapies in elderly IBD patients 187
Voluntary and controlled weight loss can reduce symptoms and proton pump inhibitor use and dosage in patients with gastroesophageal reflux disease: A comparative study 183
Manually calculated oesophageal bolus clearance time increases in parallel with reflux severity at impedance-pH monitoring 178
Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease 178
Eosinophilic esophagitis: clinical, endoscopic, histologic and therapeutic differences and similarities between children and adults 176
Lower pH values of weakly acidic refluxes as determinants of heartburn perception in gastroesophageal reflux disease patients with normal esophageal acid exposure 173
Oral sucrosomial iron is as effective as intravenous ferric carboxy‐maltose in treating anemia in patients with ulcerative colitis 172
Diagnostic delay, effectiveness and safety outcomes in a real-world cohort of patients with Crohn's disease: Data from administrative databases in Tuscany, Italy 172
Barrett's esophagus in 2016: From pathophysiology to treatment 170
Vegetal and Animal Food Proteins Have a Different Impact in the First Postprandial Hour of Impedance-pH Analysis in Patients with Heartburn 170
Intestinal histomorphological and molecular alterations in patients with Parkinson's disease 166
Esophageal testing: What we have so far 166
Adherence to mesalazine and identification of patients with ulcerative colitis in healthcare administrative databases of Tuscany (Italy) 164
Corticosteroid Treatment at Diagnosis: An Analysis of Relapses, Disease Extension, and Colectomy Rate in Ulcerative Colitis 161
Novel Prognostic Biomarkers of Mucosal Healing in Ulcerative Colitis Patients Treated With Anti-TNF: Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio 159
Antimicrobial treatment with the fixed-dose antibiotic combination RHB-104 for Mycobacterium avium subspecies paratuberculosis in Crohn’s disease: pharmacological and clinical implications 153
Low fermentable oligo-di-and mono-saccharides and polyols (Fodmaps) or gluten free diet: What is best for irritable bowel syndrome? 153
A low-FODMAP diet for irritable bowel syndrome: Some answers to the doubts from a long-term follow-up 152
Fecal Calprotectin Predicts Mucosal Healing in Patients With Ulcerative Colitis Treated With Biological Therapies: A Prospective Study 151
Functional Heartburn Overlaps With Irritable Bowel Syndrome More Often than GERD 150
Antimicrobial treatment with the fixed-dose antibiotic combination RHB-104 for Mycobacterium avium subspecies paratuberculosis in Crohn’s disease: pharmacological and clinical implications 143
Are PPI responder patients always confirmed as GERD patients? A MII-PH study. 142
Fecal calprotectin: Current and future perspectives for inflammatory bowel disease treatment 142
Time to biologic treatment and to total colectomy associated with diagnostic delay in ulcerative colitis: Analysis of an Italian regional administrative healthcare database 138
Baseline Assessment of Serum Cytokines Predicts Clinical and Endoscopic Response to Ustekinumab in Patients With Crohn’s Disease: A Prospective Pilot Study 134
The complex interplay between gastrointestinal and psychiatric symptoms in irritable bowel syndrome: A longitudinal assessment 128
HOSPITALIZATION FOR DRUG INFUSION DOES NOT INCREASE COVID INFECTION RATE, IBD RELAPSES DUE TO INFECTIONS AND LEVELS OF ANXIETY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A COMPARATIVE STUDY 127
Hospitalisation for Drug Infusion Did Not Increase Levels of Anxiety and the Risk of Disease Relapse in Patients with Inflammatory Bowel Disease during COVID-19 Outbreak 120
Effectiveness and Safety of Nonmedical Switch From Adalimumab Originator to SB5 Biosimilar in Patients With Inflammatory Bowel Diseases: Twelve-Month Follow-Up From the TABLET Registry 120
Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care 119
From bench to bedside: Fecal calprotectin in inflammatory bowel diseases clinical setting 119
Esophageal bolus contact time and chemical clearance may differentiate patients with non-erosive reflux disease: an impedance-pH monitoring study 117
Expression of Circulating let-7e and miR-126 May Predict Clinical Remission in Patients With Crohn's Disease Treated With Anti-TNF-α Biologics 114
Therapeutic drug monitoring in Crohn's disease patients treated with anti-TNF: a comparison of two techniques 102
Telemedicine and Remote Screening for COVID-19 in Inflammatory Bowel Disease Patients: Results From the SoCOVID-19 Survey 100
Fecal calprotectin could predict clinical and endoscopic response to ustekinumab therapy 99
A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian study 96
Editorial: can serum triiodothyronine-to-thyroxine (T3/T4) ratio predict safety and efficacy of biologic treatment in IBD? Authors' reply 94
Potential missed diagnoses of Crohn's disease in tertiary care: impact on drug utilization and healthcare facilities use 93
Rapid point-of-care anti-infliximab antibodies detection in clinical practice: comparison with ELISA and potential for improving therapeutic drug monitoring in IBD patients 92
Reply to Letter to the Editor: NLR and PLR as Novel Prognostic Biomarkers of Mucosal Healing in Ulcerative Colitis Patients Treated With Anti-TNF 89
Editorial: serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab—authors' reply 89
Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator 88
Letter: ustekinumab's effectiveness outcomes compared with vedolizumab in Crohn's disease-what about mucosal healing and biomarkers? 87
Ig Glycosylation in Ulcerative Colitis: It’s Time for New Biomarkers 86
Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study 85
Ulcerative proctitis treated with biologics: is it too hard to treat? 83
Vitamin d-related genetics as predictive biomarker of clinical remission in adalimumab-treated patients affected by crohn’s disease: A pilot study 82
P965 Ulcerative proctitis treated with biologics: is it too hard to treat? 80
Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients 80
The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar 79
Switching from Infliximab Originator to SB2 Biosimilar in Inflammatory Bowel Diseases: A Multicentric Prospective Real-Life Study 75
The Adherence to Infusible Biologic Therapies in Inflammatory Bowel Disease Patients during the COVID-19 Pandemic: Is It Really a Problem? 73
The PROSit cohort of infliximab biosimilar in IBD: A prolonged follow-up on the effectiveness and safety across Italy 72
Therapeutic drug monitoring is more cost-effective than a clinically based approach in the management of loss of response to infliximab in inflammatory bowel disease: An observational multicentre study 68
Editorial: serum triiodothyronine-to-thyroxine (T3/T4) ratio as biomarker of response in IBD - an open issue 64
null 49
Totale 8.624
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.749
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.749
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202199 0 0 0 0 0 0 0 0 0 0 49 50
2021/2022588 6 21 25 28 102 80 36 29 39 28 53 141
2022/2023886 103 151 85 53 89 95 15 57 166 2 70 0
2023/2024571 37 39 97 32 68 90 50 24 8 18 40 68
2024/20252.353 8 69 61 150 190 254 192 104 282 292 213 538
2025/20262.828 168 303 426 346 299 190 407 151 186 328 24 0
Totale 8.624